Role of Inflammatory Diseases in Hypertension

High Blood Press Cardiovasc Prev. 2017 Dec;24(4):353-361. doi: 10.1007/s40292-017-0214-3. Epub 2017 Jun 9.

Abstract

Chronic inflammatory diseases (CID) are characterized by an increased risk of cardiovascular (CV) morbidity and mortality. Several mechanisms, including early acceleration of subclinical atherosclerotic damage, inflammatory markers and immune system deregulation factors, have been demonstrated to strictly interplay for development and progression of atherosclerosis. Moreover, traditional CV risk factors are likely to explain at least some of the excess of CV risk in these patients. Among traditional CV risk factors, compelling evidence suggests a higher incidence and prevalence of hypertension in patients with CID in comparison to the general population. Moreover, hypertension represents an important predictor of CV events in these patients. Pathogenic mechanisms underlying the rise of blood pressure in CID are multifactorial and still poorly investigated. Indeed, multiple disease-related factors may affect blood pressure control in these patients and hypertension may affect disease prognosis and increase CV risk. Better knowledge of the complex interplay between hypertension and CID will be important to elucidate pathogenic mechanisms and to improve CV outcome in these patients. Aim of this review is to highlight available evidence on the relationship between hypertension and CID and to elucidate the multiple factors that may affect blood pressure control in these disorders.

Keywords: Cardiovascular risk; Chronic inflammatory diseases; Hypertension.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Blood Pressure*
  • Chronic Disease
  • Female
  • Humans
  • Hypertension / epidemiology*
  • Hypertension / immunology
  • Hypertension / mortality
  • Hypertension / physiopathology
  • Incidence
  • Inflammation / epidemiology*
  • Inflammation / immunology
  • Inflammation / mortality
  • Inflammation / physiopathology
  • Inflammation Mediators / immunology
  • Male
  • Middle Aged
  • Prevalence
  • Prognosis
  • Risk Assessment
  • Risk Factors
  • Signal Transduction

Substances

  • Inflammation Mediators